Protocol Ledger

NCT06331312 · Phase III · ACTIVE NOT RECRUITING

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

Interventional Phase III clinical trial protocol NCT06331312 sponsored by Novartis in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-28 Enrollment: 162 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06331312
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)162 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06331312
Protocol FieldVerified Registry Value
NCT IdentifierNCT06331312
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment162 participants (ACTUAL)
Registered Start Date2024-06-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06331312
Hospital Research SiteLocationSite Profile
Dartmouth Hitchcock Medical CenterLebanon, NHOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI